Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-10-05
2009-12-15
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C530S387300
Reexamination Certificate
active
07632499
ABSTRACT:
Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.
REFERENCES:
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6368597 (2002-04-01), Strassmann
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6468535 (2002-10-01), Lee et al.
patent: 6517835 (2003-02-01), Lee et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6858208 (2005-02-01), Lee et al.
patent: 7320789 (2008-01-01), Wolfman et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2005/0014733 (2005-01-01), Whittemore et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 2005/0143306 (2005-06-01), Junker et al.
patent: 2 333 706 (1999-04-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 94/26892 (1994-11-01), None
patent: WO 96/01845 (1996-01-01), None
patent: WO 99/06559 (1999-02-01), None
patent: WO 99/24058 (1999-05-01), None
patent: WO 99/40181 (1999-08-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 02/09641 (2002-02-01), None
patent: WO 02/10214 (2002-02-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 2004/037861 (2004-05-01), None
patent: WO 2004/058988 (2004-07-01), None
patent: WO 2004/108157 (2004-12-01), None
patent: WO 2005/094446 (2005-10-01), None
patent: WO 2006/116269 (2006-11-01), None
patent: WO 2007/024535 (2007-03-01), None
patent: WO 2007/044411 (2007-04-01), None
Ashmore, et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and ‘Double-Muscled’ Cattle,”Growth38:501-506 (1974).
Bogdanovich, et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade,”Nature420:418-421(2002).
Bogdanovich, et al., “Therapeutics for Duchenne Muscular Dystrophy: Current Approaches and Future Directions,”J. Mol. Med. 82:102-115 (2004).
Gamer, et al., “Gdf11 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol. 229:407-420 (2001).
Gamer, et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Dev. Biol. 208:222-232 (1999).
Gonzalez-Cadavid, et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-lnfected Men With Muscle Wasting,”PNAS95:14938-14943 (1998).
Gonzales-Cadavid, et al., “Role of Myostatin in Metabolism,”Curr. Opin. Clin. Nutr. Metab. Care7:451-457 (2004).
Grobet, et al., “A Deletion in the Bovine Myostatin Gene Causes the Double-Muscled Phenotype in Cattle,”Nature Genet. 17:71-74 (1997).
Hamrick, et al., “Femoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice,”Bone27:343-349 (2000).
Hamrick, et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice,”Calcif. Tissue Int. 71(1):63-68 (2002).
Hill, et al., “The Myostatin Propeptide and the Follistatin-Related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum,”J. Biol. Chem. 277:40735-40741 (2002).
Hill, et al., “Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains,”Mol. Endocrinol. 17:1144-1154 (2003).
Hoodless, et al., “Mechanisms and Function of Signaling by the TGFβ Superfamily,”Current Topics in Microbiology and Immunologypp. 236-272 (1998).
Huet, et al., “Skeletal Muscle Cell Hypertrophy Induced by Inhibitors of Metalloproteases; Myostatin as a Potential Mediator,”Am. J. Physiol. Cell. Physiol. 281:C1624-C1634 (2001).
Jiang, et al., “Characterization and Identification of the Inhibitory Domain of GDF-8 Propeptide,”Biochem. Biophys. Res. Commun. 315:525-531 (2004).
Kambadur, et al., “Mutations inMyostatin(GDF8) In Double-Muscled Belgian Blue and Piedmontese Cattle,”Genome Res. 7:910-915 (1997).
Kim, et al., “Inhibition of Preadipocyte Differentiation by Myostatin Treatment in 3T3-L1 Cultures,”Biochem. Biophys. Res. Comm., 281:902-906 (2001).
Kingsley, D.M., “The TGFβ Superfamily: New Members, New Receptors, and New Genetic Tests of Function in Different Organisms,”Genes&Devel. 8:133-146 (1994).
Kirk, et al., “Myostatin Regulation During Skeletal Muscle Regeneration,”J. Cell. Physiol., 184:356-363 (2000).
Lang, et al., “Regulation of Myostatin by Glucocorticoids After Thermal Injury,”FASEB J. 15:1807-1809 (2001).
Lee, et al., “Regulation of Myostatin Activity and Muscle Growth,”PNAS98:9306-9311 (2001).
Li, et al., “Elimination of Myostatin Does Not Combat Muscular Dystophy in dy Mice but Increases Postnatal Lethality,”AJP. 166 (2) 491-497, 2005.
Lin, et al., “Myostatin Knockout in Mice Increases Myogenesis and Decreases Adipogenesis,”Biochem. Biophys. Res. Comm., 291:701-706 (2002).
Massagué, J., “The Transforming Growth Factor-β Family,”Ann. Rev. Cell Biol.6:597-641 (1990).
McPherron, et al., “Double Muscling in Cattle Due to Mutations in the Myostatin Gene,”PNAS94:12457-12461 (1997).
McPherron, et al., “Regulation of Skeletal Muscle Mass in Mice by a New TGF-β Superfamily Member,”Nature387:83-90 (1997).
McPherron, et al., “Suppression of Body Fat Accumulation in Myostatin-Deficient Mice,”J. Clin. Invest. 109:595-601 (2002).
Muscaritoli, et al., “Therapy of Muscle Wasting in Cancer: What Is The Future?”Curr. Opin. Clin. Nutr. Metab. Care, 7:459-466 (2004).
Nakashima, et al., “Expression of Growth/Differentiation Factor 11, A New Member of the BMP/TGF β Superfamily During Mouse Embryogenesis,”Mech. Dev. 80:185-189 (1999).
Reardon, et al., “Myostatin, Insulin-Like Growth Factor-1, and Leukemia Inhibitory Factor mRNAs Are Upregulated in Chronic Human Disuse Muscle Atrophy,”Muscle Nerve, 24:893-899 (2001).
Rios, et al., “Myostatin Is An Inhibitor of Myogenic Differentiation,”Am. J. Physiol. Cell Physiol., 282: C993-C999 (2002).
Roth, et al., “Myostatin: A Therapeutic Target for Skeletal Muscle Wasting,”Curr. Opin. Clin. Nutr. Metab. Care, 7:259-263 (2004).
Sharma, et al., “Myostatin, a Transforming Growth Factor-β Superfamily Member, Is Expressed in Heart Muscle and Is Upregulated in Cardiomyocytes After Infarct,”J. Cell. Physiol., 180:1-9 (1999).
Swatland, et al., “Fetal Development of the Double Muscled Condition in Cattle,”J. Animal Sci. 38:752-757 (1974).
Thies, et al., “GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding,”Growth Factors18:251-259 (2001).
Thomas, et al., “Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation,”J. Biol. Chem., 275 (51) 40235-40243 (2000).
Tseng, et al., “Regenerated mdx Mouse Skeletal Muscle Shows Differential mRNA Expression,”J. Appl. Physiol. 93:537-545 (2002).
Tsuchida, et al., “Identification and Characterization of a Novel Follistatin-like Protein as a Binding Protein for the TGF-β Family,”J. Biol. Chem. 275:40788-40796 (2000).
Wagner, et al., “Loss of Myostatin Attenuates Severity of Muscular Dystrophy inmdxMice,”Ann. Neurol. 5
Davies Julian
Jones Bryan Edward
Korytko Andrew Ihor
Mitchell Pamela Jean
O'Bryan Linda Maureen
Eli Lilly and Company
Huff Sheela J
Wiskerchen MaryAnn
LandOfFree
Anti-myostatin antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-myostatin antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-myostatin antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4055029